Certara, Inc. (NASDAQ:CERT) Given Average Recommendation of “Hold” by Brokerages

Certara, Inc. (NASDAQ:CERT) has been assigned an average recommendation of “Hold” from the twelve brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $15.6250.

CERT has been the subject of a number of recent research reports. Craig Hallum started coverage on Certara in a research note on Monday, September 29th. They set a “buy” rating and a $16.00 price target for the company. Weiss Ratings restated a “sell (d)” rating on shares of Certara in a report on Wednesday, October 8th. KeyCorp lifted their target price on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Barclays boosted their target price on shares of Certara from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Finally, Zacks Research upgraded shares of Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th.

Insiders Place Their Bets

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the transaction, the insider directly owned 73,979 shares in the company, valued at $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CERT. Janney Montgomery Scott LLC bought a new stake in Certara during the 1st quarter valued at approximately $120,000. Northern Trust Corp lifted its holdings in shares of Certara by 4.5% during the first quarter. Northern Trust Corp now owns 916,299 shares of the company’s stock worth $9,071,000 after buying an additional 39,289 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Certara in the first quarter valued at approximately $297,000. Principal Financial Group Inc. grew its stake in shares of Certara by 2.4% in the first quarter. Principal Financial Group Inc. now owns 543,958 shares of the company’s stock worth $5,385,000 after acquiring an additional 12,513 shares during the last quarter. Finally, Brown Advisory Inc. bought a new position in Certara during the first quarter worth $238,000. 73.96% of the stock is owned by institutional investors.

Certara Trading Up 0.6%

Certara stock opened at $11.70 on Tuesday. Certara has a 12 month low of $8.64 and a 12 month high of $15.69. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The stock has a market cap of $1.88 billion, a P/E ratio of 234.05 and a beta of 1.44. The company’s fifty day simple moving average is $11.78 and its 200-day simple moving average is $11.57.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm had revenue of $104.57 million for the quarter, compared to analysts’ expectations of $104.14 million. During the same quarter in the prior year, the business posted $0.07 earnings per share. Certara’s revenue was up 12.1% on a year-over-year basis. As a group, sell-side analysts forecast that Certara will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.